Compare CELC & WING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | WING |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2017 | 2015 |
| Metric | CELC | WING |
|---|---|---|
| Price | $53.29 | $151.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 27 |
| Target Price | $150.85 | ★ $184.92 |
| AVG Volume (30 Days) | 920.9K | ★ 1.4M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 0.87% |
| EPS Growth | N/A | ★ 67.84 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $696,853,000.00 |
| Revenue This Year | N/A | $7.16 |
| Revenue Next Year | $1,921.71 | $14.63 |
| P/E Ratio | ★ N/A | $45.84 |
| Revenue Growth | N/A | ★ 11.35 |
| 52 Week Low | $53.54 | $95.82 |
| 52 Week High | $151.02 | $302.80 |
| Indicator | CELC | WING |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 53.54 |
| Support Level | N/A | $139.01 |
| Resistance Level | $72.76 | $177.19 |
| Average True Range (ATR) | 4.24 | 8.94 |
| MACD | -1.03 | -2.72 |
| Stochastic Oscillator | 0.16 | 23.41 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across over 10 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 stores, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.